MedWatch

Analysts lose confidence in Biogen Alzheimer's approval

There have been so many controversies surrounding Biogen's drug candidate for Alzheimer's disease, aducanumab, that analysts now see its approval chances as vanishingly low.

Photo: Steven Senne/AP/Ritzau Scanpix

With the deadline for the FDA (US Food and Drug Administration)'s decision on Biogen's drug aducanumab fast approaching, analysts at RBC Capital Markets are less and less convinced that the result will be in Biogen's favor, writes Fiercepharma.

Aducanumab has faced many problems throughout the regulatory process. The application was turned down by an FDA expert committee in November, and the response deadline was pushed back by the agency in January.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs